Provided by Tiger Trade Technology Pte. Ltd.

WUXI BIO

37.680
+0.1600.43%
Volume:26.28M
Turnover:988.13M
Market Cap:155.92B
PE:42.61
High:37.900
Open:36.980
Low:36.880
Close:37.520
52wk High:42.600
52wk Low:16.200
Shares:4.14B
HK Float Shares:4.14B
Volume Ratio:0.79
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.884
ROE:10.50%
ROA:5.89%
PB:3.08
PE(LYR):42.61
PS:6.90

Loading ...

WuXi Biologics Alliances Deepen Role In Complex Autoimmune And Fusion Drugs

Simply Wall St.
·
Yesterday

Wuxi Biologics (Cayman) Stock Advances 2.6% in Hong Kong

Dow Jones
·
Feb 05

Wuxi XDC Cayman Inc. verschiebt Versand der Angebotsunterlagen

Reuters
·
Feb 04

TOT BIOPHARM Delays Dispatch of Composite Offer Document

Reuters
·
Feb 04

Assessing WuXi Biologics (SEHK:2269) Valuation After New Autoimmune And Biologics Collaboration Wins

Simply Wall St.
·
Feb 04

WuXi Biologics Signs License and Research Service Agreement with Vertex Pharmaceuticals

Reuters
·
Feb 03

WuXi Biologics schließt Lizenz- und Forschungsdienstleistungsvertrag mit Vertex Pharmaceuticals für T-Zell-Engager ab

Reuters
·
Feb 03

WuXi Biologics and Vertex Sign License and Research Service Agreement for T-Cell Engager

THOMSON REUTERS
·
Feb 03

Wuxi Biologics (Cayman) Stock Slides 3.1% in Hong Kong

Dow Jones
·
Feb 02

Wuxi Biologics (Cayman) Stock Sheds 2.4% in Hong Kong

Dow Jones
·
Jan 30

WuXi Biologics and Sinorda Biomedicine Partner to Advance Bispecific Antibody for Autoimmune Diseases

Reuters
·
Jan 29

WuXi Biologics and Sinorda Biomedicine Enter Strategic Collaboration to Accelerate Development and Manufacturing of Innovative Bispecific Antibody

THOMSON REUTERS
·
Jan 29

Wuxi Biologics (Cayman) Stock Slides 2.8% in Hong Kong

Dow Jones
·
Jan 26

BRIEF-Morgan Stanley’S Long Position In WuXi Biologics (Cayman) Decreases To 2.11% On Jan 20 From 5.58%, HKEX Shows

Reuters
·
Jan 23

Morgan Stanley’s Long Position in WuXi Biologics (Cayman) Decreases to 2.11% on Jan 20 From 5.58% - HKEX

THOMSON REUTERS
·
Jan 23

New UK MHRA Certifications and PatroLab Platform Might Change The Case For Investing In WuXi Biologics (Cayman) (SEHK:2269)

Simply Wall St.
·
Jan 23

CLSA Maintains Outperform Rating on WUXI BIO (02269), Sees Enhanced Visibility for Growth Acceleration

Stock News
·
Jan 23

Wuxi Biologics (Cayman) Stock Advances 1.5% in Hong Kong

Dow Jones
·
Jan 22

Assessing WuXi Biologics (SEHK:2269) Valuation After New GMP Certifications And PatroLab Launch

Simply Wall St.
·
Jan 22

Wuxi Biologics (Cayman) Stock Falls 2.0% in Hong Kong

Dow Jones
·
Jan 20